Bristol-Myers Squibb Cruiserath

Bristol Myers Squibb CEO describes new drug for treating schizophrenia

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar disorder and Alzheimer’s disease.

NBC Connecticut · 3d

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

Mint · 3d

Bristol Myers Says New Schizophrenia Drug Off to Strong Start

(Bloomberg) -- Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna ...

Business Insider · 3d

Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older

Nasdaq7d

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

CSR Wire4d

Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year

Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...

Yahoo Finance27d

Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 78%

Every investor in Bristol-Myers Squibb Company (NYSE:BMY) should be aware of the most powerful shareholder groups. With 78% stake, institutions possess the maximum shares in the company.

Seeking Alpha28d

Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued

Bristol-Myers Squibb remains a "Buy" despite recent price increases, with intrinsic value calculations showing the stock is still undervalued. The company faces risks from patent expirations but ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results